New combo therapy shows promise for tough leukemia cases
NCT ID NCT03118466
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 42 times
Summary
This study tested whether adding the drug lenalidomide to a standard chemotherapy regimen (MEC) could help adults with acute myeloid leukemia (AML) that had come back or not responded to prior treatment. 41 patients took part. The main goal was to see how many achieved complete remission (no signs of leukemia) or complete remission without full platelet recovery. The study is complete, and results help guide future treatment options for this difficult-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02062, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.